Chicago Equity Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Chicago Equity Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,914	Closed	-$295K	–	891
2019 Q3	$295K	Hold	4,914	–	–	0.01%	781
2019 Q2	$415K	Sell	4,914 -26,715	-84%	-$2.4M	0.02%	737
2019 Q1	$3.02M	Sell	31,629 -750	-2%	-$67.3K	0.12%	240
2018 Q4	$2.29M	Buy	32,379 +4,590	+17%	+$352K	0.09%	310
2018 Q3	$2.38M	Sell	27,789 -12,950	-32%	-$1.3M	0.07%	343
2018 Q2	$4.72M	Sell	40,739 -3,360	-8%	-$335K	0.14%	201
2018 Q1	$3.57M	Buy	44,099 +31,600	+253%	+$2.43M	0.11%	257
2017 Q4	$733K	Buy	+12,499	New	+$626K	0.02%	554

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Chicago Equity Partners's ENTA Position: Q4 2019 in Review

Chicago Equity Partners sold out of Enanta Pharmaceuticals (ENTA) in Q4 2019, closing a stake of 4,914 shares — an estimated $295K sold.

Chicago Equity Partners first reported a position in ENTA in Q4 2017 and held it in 8 quarters. The position peaked at $4.72M in Q2 2018. 171 funds tracked by Wall St. Rank hold ENTA as of Q4 2019.

Chicago Equity Partners reported no remaining Enanta Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Chicago Equity Partners sold 4,914 Enanta Pharmaceuticals shares in Q4 2019, an estimated $295K.
Chicago Equity Partners first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 8 quarters.
Chicago Equity Partners's Enanta Pharmaceuticals position peaked at $4.72M in Q2 2018.
171 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2019.

Based on Chicago Equity Partners's 13F filing for Q4 2019, filed 10 Feb 2020.